Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations. Data being presented will focus on the early management of Acute Coronary Syndromes (ACS) and long-term secondary prevention of atherothrombotic events in patients who have previously suffered a heart attack.
Presentation of the data, including sub-analyses of the BRILINTA® PEGASUS-TIMI 54 study, coincides with updates to the ESC guidelines on treatment of Non-ST Segment Elevation Myocardial Infarction patients, which will be presented at the congress on Sunday, 30 August. The updated guidelines will provide insight into long term dual antiplatelet therapy for patients with a history of heart attack.
The PEGASUS-TIMI 54 study sub-analyses will provide further understanding of the types of patients most likely to benefit from long-term treatment with BRILINTA. The data will also provide insight into the relationship between the time from a patient’s last treatment with P2Y12 antiplatelet therapy and their risk of a subsequent heart attack, stroke or cardiovascular death as well as the effect of BRILINTA in this setting.
Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development, AstraZeneca, said: “It is encouraging to see guideline updates recognise the continuing risk for patients more than one year after their heart attack and consider how this risk can be managed.
We are looking forward to the presentation of the PEGASUS-TIMI 54 sub-analyses during the ESC Congress 2015 and to continuing the debate about the long-term use of dual antiplatelet therapy for these patients.”
In March 2015, based on the results of the PEGASUS-TIMI 54 study1, the US Food and Drug Administration (FDA) granted Priority Review for BRILINTA for the prevention of atherothrombotic events in patients who have previously experienced a heart attack.
Additional sub-analyses of the PEGASUS-TIMI 54 study also being presented at the ESC Congress 2015 include research into the relationship between renal function and risk of ischaemic and bleeding events, evaluated in a subset of high-risk patients with reduced renal function, and a gender comparison sub-analysis, assessing the relative safety and efficacy of ticagrelor in women versus men.
Other data highlights at the ESC Congress 2015 include:
Data from the APOLLO real-world evidence study, exploring the impact of associated risk factors (such as age ≥65 years, diabetes, history of >1 prior myocardial infarction or renal disease) on the likelihood of recurrent cardiovascular events [abstract P2467], as well as long-term national healthcare costs post-heart attack [abstract 3662], will be featured as poster presentations on Sunday 30 August and Monday 31 August.
Data from the ATLANTIC-H24 analysis, exploring the effect of pre-hospital versus in-hospital administration of ticagrelor during the first 24 hours post-procedure, specifically among patients who underwent percutaneous coronary intervention (PCI), will feature on Monday 31 August, as part of the Clinical Trial Update II – Antiplatelet therapy session [abstract 3914].
Two additional sub-analyses from ATLANTIC, exploring the study results according to gender [abstract P551] and within the French sub-population [abstract P556] will also be featured as poster presentations.
Data from the SUPPORT study demonstrating the impact of a new interactive smartphone application on improving patient adherence and quality of life [abstract 6649] will be explored during a rapid fire abstract session on Wednesday 2 September.
A VOYAGER meta-analysis examining the role of statin therapy, such as CRESTOR® (rosuvastatin) [poster P6465], in risk of atherosclerotic cardiovascular disease over a 10 year period will be presented in a poster session on Tuesday 1 September.